Multiple Sclerosis World Market Outlook to 2011

Multiple sclerosis (MS) is a chronic demyelinating disease of the CNS that causes significant disability in young adults. Worldwide, millions of people are affected by multiple sclerosis. Although there is no cure, approved treatments are available to slow the progression of MS and offer improved quality of life.

The market for these treatments has grown 15% since 2004 and continued double-digit growth is expected in the near term. Kalorama Information's: Multiple Sclerosis: A Market Briefing takes a detailed look at multiple sclerois worldwide and the market for MS treatments, as well as treatments that will be available in the future. Kalorama's study focusing on the following four treatments:

Copaxone

Avonex

Rebif

Betaseron/Betaferon

As part of its continuing coverage, this report provides:

Overview of Multiple Sclerosis and its Progression.

Complete Incidence and Prevalence Statistics For U.S. and Worldwide.

Triggers and Risk Factors of MS.

Review of Multiple Sclerosis Treatments on the Market

Market Size and Forecasts For Treatements to 2011.

Issues and Trendsfacing MS treatment

New Multiple Sclerosis Treatments in the pipleline.

As part of Kalorama's trusted information -gathering process, intensive research into company, trade and medical literature was supplemented by interviews with experts in the multiple sclerosis treatment industry. Interviews make up the source of forecast and market size figures.

The Multiple Sclerosis market is examined for the U.S., European and Japanese markets.

Published: Jun 1, 2007

110 Pages

PDF Format
Table of Contents
Price: $2,995.00 / GBP1,497.50